PreciseDx, a leader in oncology diagnostics utilizing Artificial Intelligence (AI) for innovative disease analysis, has successfully raised $20.7 million in Series B funding. This brings their total funding to $31.5 million. The funding round, led by Eventide Asset Management, includes notable participants such as Labcorp, Quest Diagnostics, and GenHenn Capital Venture.
- Funding Details
- Amount Raised: $20.7 million in Series B funding.
- Total Funding to Date: $31.5 million.
- Lead Investor: Eventide Asset Management.
- Additional Participants: Labcorp, Quest Diagnostics, GenHenn Capital Venture, and existing investors.
- Impact on Diagnostics
- Advancements in Breast Cancer Diagnostics: Faster and more accurate data delivery.
- Clinical Impact: Improved decision-making and patient outcomes.
- Future Plans: Continued clinical trials for PreciseBreast™ and preparation for market entry.
- Statements from Leadership
- Eric Converse, Founding Board Member: Highlights the role of the funding in advancing clinical trials and validation of PreciseBreast™.
- Westley Dupray, CFA, Principal at Eventide: Expresses excitement about PreciseDx’s milestones and future potential to enhance patient care and healthcare efficiency.
- Recent Achievements
- Validation Studies: Completion of analytical and clinical validation studies.
- Approvals: CLIA Standard approval and CLEP NYSDOH review for PreciseBreast™.
- Publications and Collaborations: Cost Impact Study published, new collaborations with UCLA, COTA, Baptist Health South Florida, and Baylor Scott & White Health.
- Significance of Funding
- Future Prospects: Funding supports ongoing achievements and reinforces trust in PreciseDx’s growth trajectory.
The recent Series B funding for PreciseDx® underscores the company’s progress and potential in revolutionizing breast cancer diagnostics through AI. The capital infusion will enable continued clinical validation of PreciseBreast™ and further development of its innovative diagnostic solutions.
